[HTML][HTML] The global burden of liver disease

ZM Younossi, G Wong, QM Anstee, L Henry - Clinical Gastroenterology and …, 2023‏ - Elsevier
Chronic liver disease (CLD) and its associated complications (cirrhosis and liver cancer)
cause significant mortality, morbidity, and economic burden. Published data from the World …

[HTML][HTML] Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

S Blach, S Zeuzem, M Manns, I Altraif… - The lancet …, 2017‏ - thelancet.com
Summary Background The 69th World Health Assembly approved the Global Health Sector
Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality …

Approved antiviral drugs over the past 50 years

E De Clercq, G Li - Clinical microbiology reviews, 2016‏ - journals.asm.org
Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …

Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review

O Falade-Nwulia, C Suarez-Cuervo… - Annals of internal …, 2017‏ - acpjournals.org
Background: Rapid improvements in hepatitis C virus (HCV) therapy have led to the
approval of multiple oral direct-acting antiviral (DAA) regimens by the US Food and Drug …

Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes

A Petruzziello, S Marigliano… - World journal of …, 2016‏ - pmc.ncbi.nlm.nih.gov
AIM To review Hepatitis C virus (HCV) prevalence and genotypes distribution worldwide.
METHODS We conducted a systematic study which represents one of the most …

EASL recommendations on treatment of hepatitis C 2016

European Association for The Study of The Liver - Journal of hepatology, 2017‏ - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …

Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection

JJ Feld, IM Jacobson, C Hézode… - … England Journal of …, 2015‏ - Mass Medical Soc
Background A simple treatment regimen that is effective in a broad range of patients who are
chronically infected with the hepatitis C virus (HCV) remains an unmet medical need …

Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes

SM Borgia, C Hedskog, B Parhy… - The Journal of …, 2018‏ - academic.oup.com
Abstract Background Hepatitis C virus (HCV) exhibits great genetic diversity and is classified
into 7 genotypes (GTs), with varied geographic prevalence. Until the recent development of …

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open …

X Forns, SS Lee, J Valdes, S Lens, R Ghalib… - The Lancet infectious …, 2017‏ - thelancet.com
Background The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral regimen,
glecaprevir coformulated with pibrentasvir, has shown high rates of sustained virological …

Global epidemiology and burden of HCV infection and HCV-related disease

AP Thrift, HB El-Serag, F Kanwal - Nature reviews Gastroenterology & …, 2017‏ - nature.com
Chronic HCV infection is a global health problem that affects> 184 million people worldwide.
HCV is associated with several hepatic and extrahepatic disorders, including several …